A phase I study of neoadjuvant chemotherapy with nanoparticle albumin-bound paclitaxel, doxorubicin, and cyclophosphamide (NAC) in patients with stages II-III HER2-negative breast cancer

被引：2
|
作者：
Khong, H. T.
Dyess, D. L.
Butler, T. W.
Dumlao, T. L.
机构：
[1] Univ S Alabama, Mitchell Canc Inst, Mobile, AL 36688 USA
[2] Univ S Alabama, Dept Surg, Mobile, AL 36688 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.e11519
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e11519
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A Phase II Study of Weekly Nanoparticle Albumin-Bound Paclitaxel With or Without Trastuzumab in Metastatic Breast Cancer
    Mirtsching, Barry
    Cosgriff, Thomas
    Harker, Graydon
    Keaton, Mark
    Chidiac, Tarek
    Min, Myo
    CLINICAL BREAST CANCER, 2011, 11 (02) : 121 - 128
  • [32] Phase II study of neoadjuvant bevacizumab and trastuzumab administered with albumin-bound paclitaxel (nab paclitaxel) and carboplatin in HER2+locally advanced breast cancer
    Raefsky, E.
    Castillo, R.
    Lahiry, A.
    Thompson, D. S.
    Hanson, S.
    Meng, C.
    Knauer, D.
    Trieu, V.
    Desai, N.
    Yardley, D. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [33] Randomized phase II trial of nanoparticle albumin-bound paclitaxel in three dosing schedules with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (MBC)
    Conlin, A. K.
    Hudis, C. A.
    Bach, A.
    Moynahan, M.
    Lake, D.
    Forero-Torres, A.
    Wright, G.
    Hackney, M.
    Clawson, A.
    Seidman, A. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [34] A Phase II Neoadjuvant Trial of Sequential Nanoparticle Albumin-Bound Paclitaxel Followed by 5-Fluorouracil/Epirubicin/Cyclophosphamide in Locally Advanced Breast Cancer
    Robidoux, Andre
    Buzdar, Aman U.
    Quinaux, Emmanuel
    Jacobs, Samuel
    Rastogi, Priya
    Fourchotte, Virginie
    Younan, Rami J.
    Pajon, Eduardo R.
    Shalaby, Ibrahim A.
    Desai, Ajit M.
    Fehrenbacher, Louis
    Geyer, Charles E., Jr.
    Mamounas, Eleftherios P.
    Wolmark, Norman
    CLINICAL BREAST CANCER, 2010, 10 (01) : 81 - 86
  • [35] A phase 2 study of neoadjuvant systemic therapy with eribulin followed by doxorubicin and cyclophosphamide for HER2-negative inflammatory breast cancer
    Lynce, Filipa
    Yeh, Eren D.
    Regan, Meredith M.
    Qin, Lei
    Bay, Camden P.
    Krop, Ian
    Harrison, Beth T.
    Nakhlis, Faina
    Bellon, Jennifer
    Overmoyer, Beth
    CANCER RESEARCH, 2022, 82 (04)
  • [36] Phase IB study of primary chemotherapy with paclitaxel, gemcitabine, and sunitinib in patients with HER2-negative stage II/III breast cancer.
    Lee, K. S.
    Park, I.
    Ro, J.
    Kang, H. S.
    Kim, S. W.
    Lee, S.
    Jung, S. Y.
    Kwon, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [37] A Randomized Phase II Study of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Operable HER2-negative Breast Cancer
    Yardley, Denise A.
    Shipley, Dianna
    Zubkus, John
    Wright, Gail L.
    Ward, Patrick J.
    Mani, Aruna
    Shastry, Mythili
    Finney, Lindsey
    DeBusk, Laura
    Hainsworth, John D.
    CLINICAL BREAST CANCER, 2019, 19 (01) : 1 - 9
  • [38] Tailored neoadjuvant epirubicin and cyclophosphamide (EC) and nanoparticle albumin-bound paclitaxel (nab-P) in breast cancer.
    Khasraw, Mustafa
    Mukaro, Violet Rudo
    West, Linda
    White, Karen
    Rippy, Elisabeth
    Brandt, Conrad
    Tobler, Robert
    Murphy, Caitlin Clare
    Collins, Ian M.
    Baron-Hay, Sally E.
    Ashley, David M.
    Patil, Sujata
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [39] Efficacy and Safety of Neoadjuvant Treatment with Bevacizumab, Liposomal Doxorubicin, Cyclophosphamide and Paclitaxel Combination in Locally/Regionally Advanced, HER2-Negative, Grade III at Premenopausal Status Breast Cancer: A Phase II Study
    Tampaki, Ekaterini C.
    Tampakis, Athanasios
    Alifieris, Constantinos E.
    Krikelis, Dimitrios
    Pazaiti, Anastasia
    Kontos, Michalis
    Trafalis, Dimitrios T.
    CLINICAL DRUG INVESTIGATION, 2018, 38 (07) : 639 - 648
  • [40] Efficacy and Safety of Neoadjuvant Treatment with Bevacizumab, Liposomal Doxorubicin, Cyclophosphamide and Paclitaxel Combination in Locally/Regionally Advanced, HER2-Negative, Grade III at Premenopausal Status Breast Cancer: A Phase II Study
    Ekaterini C. Tampaki
    Athanasios Tampakis
    Constantinos E. Alifieris
    Dimitrios Krikelis
    Anastasia Pazaiti
    Michalis Kontos
    Dimitrios T. Trafalis
    Clinical Drug Investigation, 2018, 38 : 639 - 648
12345